Since the bone marrow (BM) microenvironment and adipose tissue provide an attractive sanctuary for cancer progression and the acquisition of drug resistance phenotypes, 1-5 interactions between BM niche components and leukemia have recently attracted interest. However, the mechanisms underlying these complex interactions are not well understood. We previously reported that leukemic cells. through their secreted exosomes, induce microenvironment reprogramming to inhibit normal hematopoiesis and create a self-enforcing microenvironment for their own expansion.6 Here, using syngeneic acute myeloid leukemia (AML)/acute lymphoblastic leukemia (ALL) transplantation and knock-in leukemic mice models, we aimed to understand how leukemia remodels the BM niche. We describe a novel mechanism through which leukemic cells, via their exosomes, remodel BM niche subpopulations by enhancing the expression of adipose triglyceride lipase (ATGL) and hormone- sensitive lipase (HSL) enzymes in adipocytes, resulting in increased lipolysis. Furthermore, pharmacological inhibition of ATGL and HSL rescued lipolysis, preserved adipocyte morphology and reduced fatty acid oxidation in leukemic cells. Finally, we show that leukemia progression can be delayed by increasing osteoblasts and adipocytes in vivo.
As mesenchymal stem cells, osteoblasts and adipocytes together with other bone stromal cells influence hematopoietic stem cell homeostasis, regeneration and leukemic progression,7-11 we investigated these populations during leukemogenesis. As found previously,6 histological analysis of normal and leukemic mice bones revealed a reduction in mature osteoblasts and adipocyte numbers in both AML and ALL models (Figure 1A, Online Supplementary Figure S1A). Significant, progressive declines of osteocalcin (Ocn) and peroxisome proliferatoractivated bone marrow-derived receptor gamma (Pparg) mRNA levels were observed in stromal cells (GFP–CD45– Ter119–CD31–) in a leukemia burden-dependent manner in ALL and AML mice (Figure 1B and C) confirming that leukemia progression exhausts mature osteoblasts and adipocytes. Besides reductions in mature niche populations, the frequency of bone stromal cells was also significantly diminished in ALL and AML mice compared to the frequency in control animals (P<0.0001 and P<0.0001, respectively) (Online Supplementary Figure S1B and C) suggesting a progressive inhibition of all BM constituents that support functional hematopoiesis with leukemia development.
Considering the loss of BM stroma, osteoblasts and adipocytes, we next investigated the progenitor populations responsible for replenishing these cells. Sca1+CD24+ cells from BM have been shown to differentiate into osteochondrogenic and adipogenic lineages, unlike adipocyte lineage-restricted Sca1+CD24− progenitors (preadipocytes).12 Flow cytometry analysis of these distinct entities in bone stromal cells revealed that the percentage of Sca1+CD24+ multipotent progenitors (CD45− Ter119− CD31−CD166− Sca1+CD24+) within mesenchymal stem cells in MLL-AF9− and BCR-ABL+ leukemic mice was significantly reduced compared to that in healthy controls both in transplantation and knock-in leukemia models (P<0.0001 and P=0.0004, respectively (Figure 1D and E; Online Supplementary Figure S1D). Although, the frequency of preadipocytes in Sca1+ mesenchymal stem cells was significantly higher in leukemia mice (Figure 1F), the in vitro differentiation potential of preadipocytes from mice with high BM disease burden (70-85%) was severely compromised, as suggested by reduced Pparg mRNA levels (Figure 1G) and BODIPY staining (Figure 1H).
Additionally, the bona fide mesenchymal stem cell marker, PDGFRα+Sca1+(PaS), and adipocyte primed leptin receptor (LepR)13 were also analyzed. The frequency of these markers in leukemia bone stromal cells was significantly increased in a disease-burden-dependent manner (Online Supplementary Figure S2A and B). These data suggest that the leukemia-induced exhaustion of stroma and terminally differentiated adipocytes and osteoblasts pushes the mesenchymal stem cells or preadipocytes to expand to meet the renewed demands to sustain normal hematopoiesis or to support leukemia propagation, but that they fail to differentiate fully. Collectively, these data suggest that cancer-induced microenvironmental reprogramming could be a common feature of acute leukemias despite the genetic heterogeneity of these malignancies.
To gain insights into the molecular mechanisms underlying the reduction of adipocytes in leukemia, we analyzed the expression of genes involved in the pathway of triglyceride hydrolysis, ATGL (also known as PNPLA2) and hormone-sensitive lipase (HSL or LIPE, Ser563 phosphorylation site) in leukemic conditions.14 The adipocytes co-cultured with leukemic cells through a transwell for 24 h (in vitro) and white adipose tissue from leukemic mice (in vivo) exhibited upregulation of ATGL and HSL Ser563 protein expression compared to the respective controls (Figure 2A-D).
Next, to identify the driver behind this leukemia-mediated upregulation of ATGL and HSL, we analyzed leukemia exosomes. The exosomes used in the study were validated using standard markers (Online Supplementary Figure S2C-E). When co-cultured with adipocytes, the leukemia exosomes enhanced adipocytespecific ATGL and phosphorylated HSL (Ser563) protein levels unlike their normal exosome counterparts (Figure 2E), initiating the lipolysis cascade, suggesting cargo-specific differences between leukemic and normal BM exosomes. Next, we observed a significant upregulation of ATGL in white adipose tissue from leukemic mice (Figure 2F) and significantly reduced levels of a lipid dropletassociated protein, perilipin, in BM plasma, suggesting an inverse correlation between perilipin and ATGL expression (Figure 2G). Single-cell transcriptomics analysis of human BM stroma from ALL patients and healthy controls corroborated the leukemia models and in vitro findings and showed an upregulation of LIPE and PNPLA2 gene expression in leukemia stromal cells (Figure 2H). Furthermore, evaluating the clinical significance of these genes related to triglyceride catabolism, we analyzed the RNA sequencing data from the published TARGET phase-II ALL study datasets15 and observed that overexpression of LIPE and PNPL2 genes is associated with inferior overall survival in ALL patients (Online Supplementary Figure S2F), highlighting the importance of these genes in leukemia-induced microenvironmental dysregulation.
Extending the working hypothesis that exosome-mediated adipose dysfunction favors leukemia growth, we cultured adipocytes with 10 mg of exosomes derived from healthy subjects, leukemia cell lines and an AML patient (COH202) for 24 h. The adipocytes cultured with leukemia exosomes exhibited enhanced levels of interleukin-1β, interleukin-6, tumor necrosis factor-α and CCL3 mRNA transcripts compared to controls (Figure 2I), suggesting that some of the effects of exosomes on adipocyte differentiation might be attributed indirectly to these pro-inflammatory cytokines (Online Supplementary Figure S3A-C) and perhaps may also be responsible for the differentiation block. This is the first study establishing a role for leukemic exosomes in the induction of adipocyte atrophy by upregulation of ATGL/HSL lipolytic enzyme activity, directly or through inflammatory cytokines.
As a proof of principle, we first cultured the adipocytes with cytokines, AML exosomes alone or in the presence of atglistatin (an ATGL inhibitor) in nutrient-deprived conditions for 48 h. AML cells cultured in these exosome/ cytokine conditioned media (CM) had lower apoptosis, possibly by providing lipid substrates from adipocytes to drive mitochondrial β-oxidation (an alternate energy pathway) in leukemic cells during nutrient deficiency. However, atglistatin treatment increased apoptosis by blocking ATGL-mediated free-fatty acid (FFA) release (Figure 2J and K). The inhibition of FFA resulted in reduced leukemic fatty acid oxidation, evidenced by reduced mitochondrial Cpt1a gene expression (Figure 3A; Online Supplementary Figure S3D).
Atglistatin or HSL inhibitor (CAY10499) treatment also reversed the leukemia CM-induced reductions in adipocyte size (Figure 3B), possibly by inhibiting exosome- induced triglyceride breakdown. Since leukemiainduced adipocyte breakdown releases FFA into the surrounding tumor environment to drive the leukemic cells’ energy processes, we hypothesized that atglistatin or CAY10499 could inhibit FFA release and hence lower the uptake by leukemia cells. To test this hypothesis, we used adipocytes with fluorescently labeled FFA analogs and observed that atglistatin or CAY10499 treatment could significantly reduce BODIPY transfer in leukemic cells (Figure 3C).
Next, we evaluated the benefit of ATGL inhibition in the context of the resistance to chemo/radiotherapy induced by adipocytes and leukemic exosomes. MV4-11 cells were cultured in control or AML adipocyte CM together with or without atglistatin and 5 nM quizartinib (a tyrosine kinase inhibitor) in nutrient-deprived conditions. Compared to treatment with quizartinib alone, the atglistatin and quizartinib combination significantly reduced the survival advantage mediated by leukemia exosome-induced lipolysis, suggesting that atglistatin could be used as combination therapy with quizartinib to enhance its efficacy on AML cells by limiting nutrients released from adipocytes (Figure 3D).
Similarly, atglistatin also increased radiation-induced leukemia killing to overcome the adipocyte-induced resistance of leukemia to radiotherapy (Figure 3E). We further proved that leukemia-specific ATGL is essential for leukemia cell proliferation and showed that the proliferation could be inhibited pharmacologically by atglistatin in a dose-dependent manner (P=0.001 and P<0.0001 at day 4 at a doses of 50 mM and 100 mM atglistatin, respectively) (Figure 3F) or by shRNA-mediated genetic knockdown of the ATGL gene (P<0.0001 at day 4) (Figure 3G, Online Supplementary Figure S3E).
Since losses of osteoblasts and adipocytes are key features during leukemia progression, we hypothesized that increasing osteoblast or adipocyte content pharmacologically with either zoledronic acid (osteoblasts) or GW1929 (adipocytes) might delay disease development. The treated mice stroma exhibited increased levels of Ocn and Pparg genes in BM stroma providing a functional validation of the increases in osteoblast and adipocyte numbers (Online Supplementary Figure S4A and B). Furthermore, zoledronic acid or GW1929 treatment invivo prolonged the survival of AML and ALL mice (Online Supplementary Figure S4C-E), confirming the earlier belief of a role of osteoblasts and adipocytes in assisting normal hematopoiesis to delay leukemia progression.
In conclusion, we discovered that leukemia induces defective preadipocyte expansion and describe a novel mechanism of leukemic exosome-induced adipocyte loss through the activation of lipolytic genes. Finally, leukemia- or exosome-induced niche reprogramming could be rescued by GW1929 and zoledronic acid to limit the progression of leukemia. This study further strengthens our earlier observations of leukemia exosomeinduced BM microenvironmental dysregulation to favor leukemia propagation. Taken together, these findings provide a strong rationale for targeting the defective niche with leukemia exosome inhibition and normalizing BM niche components with pharmacological agents in conjunction with conventional therapies.
- Received January 9, 2020
- Accepted September 4, 2020
Disclosures: AS provides consulting for Amgen and Stemline and is on the speakers’ bureau for the former company. SKH receives honoraria from and consults for Janssen Research & Development, LLC. All other authors declare that they have no competing financial interests.
Contributions: BK, MO, JB, SSM, PV and LEP performed experiment; BK and SKH conceived the idea; BK designed experiments, interpreted data and wrote the manuscript; AS, AS, GM and SKH provided the leukemia patients’ samples; SSM, JS, GM and SKH edited the manuscript. All authors read and approved the paper.
this study was supported by grants to SKH (1R01CA154491, 2R01CA154491), City of Hope Cancer Center (P30CA033572) and American Cancer Society Grant 128766-RSG-15-162(CCC). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or other funding agencies.
We would like to thank Dr Michael Kahn, Molecular Medicine, COH, for carefully reviewing the manuscript. We also thank Donna Isbell of the Animal Resource Center for animal care, Analytical Cytometry Core for flow cytometry support and Dr. Xiwei Wu from the Integrative Genomics Core laboratory for help with the single cell sequencing. Research reported in this publication also included work performed in the microscopy and pathology cores at City of Hope.
- Ye H, Adane B, Khan N. Leukemic stem cells evade chemotherapy by metabolic adaptation to an adipose tissue niche. Cell Stem Cell. 2016; 19(1):23-37. https://doi.org/10.1016/j.stem.2016.06.001PubMedPubMed CentralGoogle Scholar
- Tabe Y, Yamamoto S, Saitoh K. Bone marrow adipocytes facilitate fatty acid oxidation activating AMPK and a transcriptional network supporting survival of acute monocytic leukemia cells. Cancer Res. 2017; 77(6):1453-1464. https://doi.org/10.1158/0008-5472.CAN-16-1645PubMedPubMed CentralGoogle Scholar
- Mendez-Ferrer S, Bonnet D, Steensma DP. Bone marrow niches in haematological malignancies. Nat Rev Cancer. 2020; 20(5):285-298. https://doi.org/10.1038/s41568-020-0245-2PubMedGoogle Scholar
- Sheng X, Tucci J, Parmentier JH. Adipocytes cause leukemia cell resistance to daunorubicin via oxidative stress response. Oncotarget. 2016; 7(45):73147-73159. https://doi.org/10.18632/oncotarget.12246PubMedPubMed CentralGoogle Scholar
- Schepers K, Campbell TB, Passegue E. Normal and leukemic stem cell niches: insights and therapeutic opportunities. Cell Stem Cell. 2015; 16(3):254-267. https://doi.org/10.1016/j.stem.2015.02.014PubMedPubMed CentralGoogle Scholar
- Kumar B, Garcia M, Weng L. Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Leukemia. 2018; 32(3):575-587. https://doi.org/10.1038/leu.2017.259PubMedPubMed CentralGoogle Scholar
- Frisch BJ, Ashton JM, Xing L, Becker MW, Jordan CT, Calvi LM. Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. Blood. 2012; 119(2):540-550. https://doi.org/10.1182/blood-2011-04-348151PubMedPubMed CentralGoogle Scholar
- Boyd AL, Reid JC, Salci KR. Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. Nat Cell Biol. 2017; 19(11):1336-1347. https://doi.org/10.1038/ncb3625PubMedGoogle Scholar
- Zhou BO, Yu H, Yue R. Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nat Cell Biol. 2017; 19(8):891-903. https://doi.org/10.1038/ncb3570PubMedPubMed CentralGoogle Scholar
- Mendez-Ferrer S, Michurina TV, Ferraro F. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature. 2010; 466(7308):829-834. https://doi.org/10.1038/nature09262PubMedPubMed CentralGoogle Scholar
- Mattiucci D, Maurizi G, Izzi V. Bone marrow adipocytes support hematopoietic stem cell survival. J Cell Physiol. 2018; 233(2):1500-1511. https://doi.org/10.1002/jcp.26037PubMedGoogle Scholar
- Ambrosi TH, Scialdone A, Graja A. Adipocyte accumulation in the bone marrow during obesity and aging impairs stem cell-based hematopoietic and bone regeneration. Cell Stem Cell. 2017; 20(6):771-784.e6. https://doi.org/10.1016/j.stem.2017.02.009PubMedPubMed CentralGoogle Scholar
- Yue R, Zhou BO, Shimada IS, Zhao Z, Morrison SJ. Leptin receptor promotes adipogenesis and reduces osteogenesis by regulating mesenchymal stromal cells in adult bone marrow. Cell Stem Cell. 2016; 18(6):782-796. https://doi.org/10.1016/j.stem.2016.02.015PubMedGoogle Scholar
- Lass A, Zimmermann R, Oberer M, Zechner R. Lipolysis - a highly regulated multi-enzyme complex mediates the catabolism of cellular fat stores. Prog Lipid Res. 2011; 50(1):14-27. https://doi.org/10.1016/j.plipres.2010.10.004PubMedPubMed CentralGoogle Scholar
Figures & Tables
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.